Therefore, how to improve the chemosensitivity of bladder cancer with low expression of MSH2, as well as elucidating the underline mechanisms of MSH2-mediated CDDP sensitivity are of paramount importance. The gene discussed is MSH2; the disease is urinary bladder cancer.